Workforce Development: Professional Enhancement and Career Advancement
Monday, April 1, 2019
6:30-8:30 p.m. ET
AACR Annual Meeting 2019
New in 2019, organized in collaboration with the Associate Membership Council (AMC), Minorities in Cancer Research (MICR) Council, Science Education and Career Advancement Committee and Women in Cancer Research (WICR) Council, this session is designed to assist with the professional and career development of investigators at all career levels. The session will consist of informal small-group conversations at roundtables with representatives from varying roles in the academic, industry, and government sectors. Participants will have the opportunity to informally speak with a roundtable mentor about his/her experiences, successes, and lessons learned that have helped establish the mentor’s career path.
This Professional Advancement session provides students, postdoctoral candidates, and junior faculty the opportunity to discuss important career development issues and survival skills with senior establish scientists. The session will be broken up into two rounds with approximately 10 participants per table informally speaking with a roundtable mentor. After the first round is complete, participants can choose to remain with their current roundtable mentor or meet with a different mentor for additional networking opportunities.
Participating Senior Scientists
Please refer to the list of senior scientists below who are participating at the AACR Annual Meeting 2019 in Atlanta, Georgia.
Participating Senior Scientists from 2019 in Alphabetical Order
- A. William Blackstock, MD
- Wayne D. Bown, PhD
- Carlos A. Casiano, PhD
- John M. Carethers, MD, MACP
- Adrienne D. Cox, PhD
- Marcia R. Cruz-Correa, MD, PhD
- Yves A. DeClerk, MD
- Laura Fejerman, PhD
- Kevin L. Gardner, MD, PhD
- Elizabeth A. Harrington, PhD
- Chanita Hughes-Halbert, PhD
- Robert T. Jones, BS
- Judith Salmon Kaur, MD
- K. Sean Kimbro, PhD
- Rick A. Kittles, PhD
- Sailaja Koduri, PhD
- Beverly D. Lyn-Cook, PhD
- Sofia D. Merajver, MD, PhD
- Kim L. O'Neill, PhD
- Electra D. Paskett, PhD, MSPH
- Timothy R. Rebbeck, PhD
- Victoria M. Richon, PhD
- Judith S. Sebolt-Leopold, PhD
- Victoria L. Seewaldt, PhD
- Christopher Sistrunk, PhD
- Louis M. Staudt, MD, PhD
- Mariana C. Stern, PhD
- Elizabeth L. Travis, PhD
- José G. Treviño, MD
- Ashani Weeraratna, PhD
- Danny R. Welch, PhD
- Jonathan Weist, PhD
- Robert Winn, MD
- Clayton Yates, PhD
A. William Blackstock, MD
Professor and Chair, Department of Radiology
Wake Forest University
Winston Salem, North Carolina
Top of Page
Dr. Blackstock is professor and chair of the Department of Radiation Oncology at the Wake Forest University (WFU) School of Medicine and director of the Clinical Research Program at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center. He received his undergraduate degree from WFU and his medical degree from the East Caroline University Brody School of Medicine. He completed a residency in radiation oncology at the University of North Carolina at Chapel Hill and a three-year NCI-funded fellowship in translational radiation oncology. He has been chair at WFU for the past eight years.
Dr. Blackstock remains active in translational clinical research, having served as vice-chair of the GI Committee in the Alliance/CALGB cooperative group and co-vice chair of the Radiation Oncology committee. In addition to serving on the NCI Clinical Oncology study section (2003-2006), he served on the NCI Pancreatic Task Force, Gastrointestinal Steering committee and co-chair of the Thoracic Malignancy Steering Committee (2013-2016). He recently completed service on the NCI Board of Scientific Counsel Intramural Program.
Dr. Blackstock has been the lead investigator of several NCI-funded grants including principal investigator of an NCI-funded T32 fellowship focused on translational radiation oncology. He currently serves on the external advisory board for several NCI/NIH funded training programs. He has served as faculty for the Methods in Clinical Research workshops in Vail and in the Netherlands. He has published over 100 peer-reviewed manuscripts and has/is currently serving on the editorial board for several journals.
"Like most things in life, it's about creating opportunities and having the wisdom (or a mentor with the wisdom), to identify those opportunities that will keep life interesting."
Chair of the Department of Molecular Pharmacology, Physiology and Biotechnology
Providence, Rhode Island
A nationally recognized leader in research on sigma receptors, Wayne Bowen, PhD isTop of Page
generally credited with the discovery and initial characterization of the sigma-2 receptor. He has shown that activation of sigma-2 receptors induces apoptotic cell death and, therefore, they may serve as regulators of cell proliferation and survival. He has most recently provided evidence that sigma-2 receptors may play a role in metabolic regulation in cancer cells. Trained initially as a chemist, Dr. Bowen maintains a strong interest and involvement in medicinal chemistry and drug design, particularly in relation to the development of selective sigma receptor agonists and antagonists. He is exploring these compounds as potential anti-neoplastic, tumor diagnostic and neuroprotective agents.
Dr. Bowen co-directs the core pharmacology course for the molecular pharmacology and
physiology (MPP) graduate program at Brown. In addition, he contributes to endocrinology and neuroscience courses for Brown University undergraduates. He has served as chair of the
department of molecular pharmacology, physiology and biotechnology since 2007.
Dr. Bowen is a member of the Society for Neuroscience, the International Brain Research
Organization/World Federation of Neuroscientists and the American Association for Cancer
Research. He is the recipient of numerous awards and honors and has performed service on
NIMH and NIDA Study Sections. Dr. Bowen's research has been funded by NIDA, NINDS,
NIDDK, the Rhode Island Science and Technology Advisory Council and a Salomon Award
from Brown University.
Professor and Associate Director, Center for Health Disparities and Molecular Medicine
Loma Linda University School of Medicine
Loma Linda, California
Dr. Casiano is tenured professor of microbiology at Loma Linda University School of Medicine and associate airector of the Center for Health Disparities and Molecular Medicine. He received a PhD in microbiology at the University of California-Davis before completing postdoctoral training at The Scripps Research Institute-La Jolla. During the past 20 years Dr. Casiano has maintained an extramurally funded research program focused on prostate cancer, and has contributed to the implementation of NIH-funded programs in health disparities research and diversity training at LLU. He has been a mentor to over 60 research trainees. Dr. Casiano has published 75 peer-reviewed publications and 15 invited scientific book chapters, and has been invited speaker at numerous national and international conferences. He currently serves as member and chair of grant review panels for the NIH and the DOD. Dr. Casiano is an active member of the AACR, having served as chair of the MICR. He has been the recipient of several awards, including the LLU Hispanic Alumni Association Award for Service to the Hispanic Community, Association for Latino Students Award, School of Medicine Distinguished Service Award, and the AACR-MICR Award in Recognition to Contributions to the Development of Minority Scientists in Cancer Research.
"As you pursue a cancer career in academia, bear in mind that you will face enormous competition for funding and resources. It is therefore of upmost importance that your predoctoral and postdoctoral training provide you with essential skills and tools that will facilitate developing a funded research program and a professional network of collaborators with different expertise and from multiple disciplines. Building an academic career in cancer research should not be the endeavor of a soloist, but the lifetime passion of a skillful player in a large symphony of talented researchers."Top of Page
John M. Carethers, MD, MACP
C. Richard Boland Distinguished University Professor, John G. Searle Professor and Chair, Department of Internal Medicine, Professor, Human Genetics
University of Michigan
Ann Arbor, MichiganNegotiations for Jobs, Salaries, and Promotions (Academia) – Table #25
Dr. Carethers is the C. Richard Boland distinguished university professor and John G. Searle professor and chair of the Department of Internal Medicine at the University of Michigan. Appointed chair in November 2009, he oversees 880 faculty in their academic, clinical, and teaching roles. Dr. Carethers is a trained gastroenterologist and physician-scientist who focuses his research in the area of colon cancer genetics. He received both his BS in biological sciences and MD from Wayne State University in Detroit, Michigan, and did his internship and residency in internal medicine at Massachusetts General Hospital in Boston, followed by a fellowship in gastroenterology at the University of Michigan. He was then recruited to UC San Diego where he grew his research laboratory focused on DNA repair pathways and hereditary colon cancer syndromes. He held leadership roles as gastroenterology fellowship director, gastroenterology section chief at the San Diego VA Hospital, then division chief for gastroenterology and hepatology at UC San Diego prior to coming to the University of Michigan. He has held multiple NIH and VA grants, and has published over 200 manuscripts. He is an elected member of ASCI, AAP (serving as president in 2018-2019), NAM, and the American Academy of Arts & Sciences, and former chair of the Minorities in Research Council of the AACR.Top of Page
“In academia, the end game of negotiation for a position should be a marriage, meaning that (a) the potential faculty member has an opportunity to learn and grow in academia, has access to mentorship, is willing to work hard to contribute to science and obtain external funding, and has a pathway for promotion, and (b) the institution obtains a quality faculty member that can enhance its reputation, can bring in external resources and recognition, and can contribute eventually to the operation of the institution. The institution generally provides initial support with the ‘payoff’ later from the faculty member. Knowing that balance is key – as it should not be one-sided.”
Adrienne D. Cox, PhD
Professor, Lineberger Comprehensive Cancer Center, Depts. Radiation Oncology & Pharmacology
University of North Carolina
Chapel Hill, North Carolina
As a young National Merit Scholar at Pomona College, Adrienne Cox became excited by the power of molecular and cell biology to uncover the mechanisms that drive cancer. Dr. Cox earned her interdisciplinary PhD at Eastern Virginia Medical School and completed her postdoctoral training at what is now the Sanford Burnham Prebys Medical Discovery Research Institute. She is professor of radiation oncology and chief of the Division of Cancer Research in that department at the University of North Carolina at Chapel Hill (UNC-CH). She is also professor of pharmacology and a member of the Lineberger Comprehensive Cancer Center, where her laboratory is located. Her research expertise ranges from basic mechanisms of small GTPase (Ras and Rho family) localization and function, to translational studies of molecularly targeted anti-cancer therapeutics. She has consulted on these topics for both biotech and pharmaceutical companies, and reviewed cancer-related grants for local, national and international agencies. Long dedicated to training and mentoring scientists at all levels, Dr. Cox teaches in UNC-CH's School of Medicine, is faculty advisor for the Science Writing and Communication Club (thepipettepen.com), directs UNC-CH's NCI-funded T32 Cancer Cell Biology Training Program, and serves on numerous internal and external advisory committees including those for faculty promotion.
"Some of the most helpful advice I got as a junior investigator was: Don't panic - all you can do is your best. If you start writing your manuscripts well before you think you really have a story, then you'll be able to see more quickly where the holes are, and will also be less likely to generate orphan data. Seek plenty of feedback on your grant proposals well before they are due. Network, network, network! The best writers of recommendations are not necessarily the people who know you best; they are people who will be perceived as prestigious by committee members who don't know your field. There's no "good time" to have kids; just do it.
Advice I wish I'd gotten and/or taken: Learn early what components your tenure packet will require, and keep a running tally of all that information as you go along rather than waiting until it's time to assemble it for submission. When something isn't working out or is a poor match for you (new hire, research direction, whatever), cut your losses quickly and move on.
Some of the best advice I've given: When trying to decide among options, think what your 10-years-in-the-future self would wish you had done. If you can't choose because you like all your options, then any choice is likely to lead to a good outcome, so don't sweat it. Not everyone can build a whole wall; you can be proud of contributing a few well-constructed bricks. Rigorous science is not only more useful than sloppy science - it's also more interesting and fun. When in doubt, ask!" Top of Page
Marcia R. Cruz-Correa
Professor of Medicine, Biochemistry and Surgery, Cancer Center
University of Puerto Rico School of Medicine
San Juan, Puerto Rico
Dr. Cruz-Correa is a gastroenterologist and physician scientist with a main focus on hereditary cancer and chemoprevention intervention studies. She was formally trained in clinical research and genetic epidemiology and has over 100 peer reviewed publications. She has received continuous funding from the NIH and private foundations for over 15 years. Has been involved in leadership positions including the Deanship for Research at the UPR, is chair-elect for the AACR Women in Cancer Research Council, previous AACR MICR Council chair and was a member of the NCI National Advisory Board (presidential appointment). She has trained over 50 students at different levels of their career, and has been recognized as with several mentorship awards including the NCI Center for Reducing Cancer Health Disparities.
"Keep positive, be curious, surround yourself with people of value. Finding a mentor(s) that is willing to invest the time in your development; but remember a true mentoring relationship requires both the mentee and the mentor to be engaged. Always pass it forward, this is the best way to grow."Top of Page
Yves A. DeClerck, MD
Children's Hospital Los Angeles, University of Souther California
Los Angeles, California
Dr. DeClerck is the associate director for training and education at the USC-Norris. In this position Dr. DeClerck oversees and enhances all education and training activities at the Cancer Center. He collaborates with other senior leaders, program leaders and members to fully outline and address the unmet needs and opportunities for training and education at USC-Norris and to identify and leverage existing training and educational activities and resources available at the Keck School of Medicine, CHLA and USC undergraduate campuses. "My goal is to make sure that USC-Norris is well equipped to stimulate interest in cancer among young individuals from elementary school to the postgraduate level, and that trainees are well prepared to work in a transdisciplinary and convergent research environment that will be necessary to address the complex question of how to eradicate cancer."
Dr. DeClerck is a professor of pediatrics and biochemistry and molecular medicine at CHLA and USC, and holds the Richard Call Family endowed chair in pediatric research innovation. Since joining USC in 1980, he has led an NIH funded research program that focuses on the tumor microenvironment and in particular on the investigation of mechanisms of interaction between tumor cells and the extracellular matrix and stromal cells. In addition to his research program, Dr. DeClerck is also the PI of a long-standing NIH T32 postdoctoral training grant and has co-led the USC-Norris TME Program for 25 years.
Dr. DeClerck has been the recipient of an American Cancer Society junior faculty award, the 1991 H. Russell Smith Award for Innovation in Pediatric Cancer Research, the CHLA Associate and Affiliates Chair in Tumor Biology, and the 2013 USC Associates Award for Creativity in Research.Top of Page
Laura Fejerman, PhD
University of California San Francisco
San Francisco, California
Dr. Fejerman is an associate professor at the UCSF Department of Medicine. She focuses on the discovery of genetic and non-genetic factors that contribute to breast cancer risk and prognosis in Latinas. Her past work established a relationship between genetic ancestry and breast cancer risk, where higher European ancestry in U.S. and Mexican Latinas was associated with an increased risk. Her subsequent research has built upon this observation, exploring genetic variants, through admixture mapping and genome-wide association approaches, as well as the possible environmental and lifestyle related factors, and ancestry-gene interactions. Recent work explores disparities in breast cancer prognosis by genetic ancestry in Latinas and its potential causes.Top of Page
Kevin L. Gardner, MD, PhD
Columbia University College of Physicians and Surgeons
New York, New York
Top of Page
Elizabeth A. Harrington, PhD
Cambridge, United Kingdom
Dr. Harrington joined AstraZeneca in 2011 and is the UK head of Translational Science for oncology and leads the lynparza translational science team. During the past eight years her department has led the development and execution of proof of mechansim, proof of principle and precision medicine biomarker strategies for over 30 programs from lead optimization to life cycle management. Areas of research focus include DNA damage and repair, PI3K/AKT/mTOR, RTK, Ras signalling, anti-hormonal therapies and immune oncology. She has over 25 years of oncology experience including an 19-year career in the pharmaceutical industry. Dr. Harrington formerly led the Oncology Signalling group and the target validation / lead identification teams at Merck Research Labs in Boston. During her career at Merck, Dr. Harrington led translational science initiatives for multiple programs including Zolinza (HDAC inhibitor) and MK-8033 (c-Met inhibitor). Prior to joining Merck, Dr. Harrington served as the biology program lead for several kinase programs including VX-680 (Aurora kinase inhibitor) at Vertex Pharmaceuticals in the UK.
Dr. Harrington began her career with a BA in biology from Oxford University. She obtained her PhD in oncology at the Imperial Cancer Research Fund (now Cancer Research UK) where she studied the molecular regulation of apoptosis in Gerard Evan's lab. She then conducted postdoctoral studies focused on cell cycle regulation and DNA damage response in Ed Harlow's lab (MGH Cancer Centre / Harvard Medical School).Top of Page
Chanita Hughes-Halbert, PhD
Charleston, South Carolina
Dr. Hughes-Halbert is a professor in the Department of Psychiatry and Behavioral Sciences and AT&T Distinguished Endowed Chair for Cancer Equity at the Hollings Cancer Center at the Medical University of South Carolina (MUSC). She is also associate dean for assessment, evaluation, and quality improvement in the College of Medicine at MUSC.
A nationally recognized expert in cancer disparities research and behavioral science, Dr. Hughes-Halbert's research focuses on understanding barriers to clinical trial participation in underserved communities and developing population-based interventions to reduce disparities in local settings. Her interest in minority health and health disparities is very personal for Dr. Hughes-Halbert as she lost both her mother and an aunt to cancer.
Dr. Hughes-Halbert is the recipient of numerous honors and awards, including the American Cancer Society Cancer Control Award, Chair-Elect for the American Association for Cancer Research Minorities in Cancer Research Council, and the MUSC Leadership Fellowship Award. Dr. Hughes-Halbert was the first woman and first African American from South Carolina elected to join the National Academy of Medicine and has authored over 100 peer-reviewed scientific articles.Top of Page
Robert T. Jones, BS
Robert (Bob) T. Jones is a student in the University of Colorado Medical Scientist Training Program (MSTP), where he is currently a PhD Candidate in the Pharmacology graduate program. He earned his Bachelor of Science degree from the University of Michigan – Dearborn. After his undergraduate training, Bob spent several years working as a research technician at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital where he studied the genomic underpinnings of numerous cancer types, with a particular focus on primary brain tumors and brain metastases. The work he did during this period inspired his decision to pursue dual MD/PhD training at the University of Colorado, where he is currently studying the molecular determinants of chemosensitivity in bladder cancer. Throughout his training, Bob has been passionate about addressing some of the unique challenges faced by his fellow early-career trainees. He is an active voice for early-career researchers within the AACR and has helped create several new professional development and career advancement opportunities for students through the AACR. Mr. Jones is the current chair-elect of the AACR Associate Member Council (AMC), where he will focus on finding better ways for the AACR and AMC to engage earlier-stage associate members who are transitioning, or who have recently transitioned, to graduate or medical school.
"Find excellent mentors throughout your training. Identify both senior and junior faculty, as well as peers; all of whom will be critical in helping you navigate your training and career thereafter. A good mentor will be able to help you structure your training in a way that balances your education, professional development, and will enjoy watching you grow. They will be able to tell you what opportunities to pursue and which to invest less time in. They share their experiences with you to help you see the best path forward for your career. This shouldn't be just one person, rather try to identify a few people who genuinely want for you to succeed. When I look back at my career thus far, I can say with absolute confidence that if it were not for finding excellent mentorship at each stage in my training, I wouldn't be where I am today."
Top of Page
Professor of Oncology
Dr. Kaur has 30 years of experience mentoring minority researchers and my passion for training the next generation of cancer researchers. She have been on the K12 advisory board for Mayo Clinic since 2000. Dr. Kaur has Master's Faculty Privileges in Clinical and Translational Sciences. In addition she has served on the trans NIH and HHS Disparities Progress Reviews and serve on numerous journal review boards. She has been funded as a health disparities researcher since 2000 and serve as faculty for a course for minority junior researchers in collaboration with the Roswell Park Cancer Institute since 2014.
"The key to successful collaborations is laying out roles and responsibilities and realistic timelines.Top of Page
Associate Professor, Biological and Biomedical Sciences
North Carolina Central University
Durham, North Carolina
Dr. Kimbro is an associate professor of biology at the North Carolina Central University, Durham, North Carolina. He also serves as the principle investigator for the Center for Translational Health Equality Research. A Center created to provide infrastructure for the study of various health disparities in the North Carolina, with emphasis on cardiovascular metabolic disparities.
Dr. Kimbro received his undergraduate from Washington University in St. Louis, Missouri and his PhD in molecular and microbiology from Indiana University, Bloomington, Indiana. From 1993 to April 1995, he was a postdoctoral fellow at Harvard Medical School and from 1995 to 1997 a fellow at the National Institutes of Health, National Institute of Environmental Health Sciences. Dr. Kimbro was later an associate professor at Clark Atlanta University, Department of Biological Sciences, in Atlanta, Georgia. In 2004, Dr Kimbro was recruited to direct the NIH Center of Excellence at Winship Cancer Institute, for which he help conceive. He was later recruited to North Carolina Central University to be the director of the Julius L. Chambers Biomedical/Biotechnology Research Institute in 2010. In 2014, Dr. Kimbro received funding to continue his research in cancer health disparities and returned to the lab to study immunity and breast/prostate cancers including Type 2 diabetes and obesity.Top of Page
Rick A. Kittles, PhD
Professor and Funding Director of the Division of Health Equities, Department of Population Sciences
City of Hope
Duarte, CaliforniaCommunicating your Research – Table #17
Dr. Kittles is professor and founding director of the Division of Health Equities within the Department of Population Sciences at the City of Hope (COH). He is also associate director of health equities of COH Comprehensive Cancer Center. Dr. Kittles is well known for his research of prostate cancer and health disparities among African-Americans. Dr. Kittles’ research has focused on understanding the complex issues surrounding race, genetic ancestry, and health disparities. Dr. Kittles received a PhD in biological sciences from George Washington University in 1998. His first faculty appointment was at Howard University where he helped establish the National Human Genome Center at Howard University.
Over the last 20 years he has been at the forefront of the development of ancestry-informative genetic markers, and how genetic ancestry can be quantified and utilized in genomic studies on disease risk and outcomes. His work has shown the impact of genetic variation across populations in pharmacogenomics, biomarker discovery, and disease gene mapping. Although a major focus of Dr. Kittles’ work over the past years has been on measuring and utilizing West African admixture in studies of genetic disease among African-Americans, presently he is expanding his research focus to further include Latino and Native American populations to further enhance the robustness of the experimental design of his research studies. Dr. Kittles has NIH-funded projects to study genetic and environmental modifiers of serum 25-hydroxyvitamin D levels in order to improve our understanding of the role serum Vitamin D plays in health disparities. He is leading a multi-site collaboration studying modifiers of serum 25-hydroxyvitamin D [25(OH)D] levels and their role on prostate cancer susceptibility.
In 2010 Dr. Kittles was named in Ebony magazine’s “The Ebony Power 100.” I selected the nation's top 100 African-American "power players" in sports, academia, religion, business, environment, science and technology, entertainment, arts and letters, fashion, politics, media, activism and health. In March of 2012 Dr. Kittles presented the Keynote Address to the United Nations General Assembly, “International Day of Remembrance of Victims of Slavery and the Transatlantic Slave Trade.” Recently Dr. Kittles was named by The Huffington Post as one of “50 Iconic Black Trailblazers Who Represent Every State In America.”
Dr. Kittles has published over 160 research articles on prostate cancer genetics, race and genetics, and health disparities.
Top of Page
Sailaja Koduri, PhD
Program Director, NIGMS
National Institute of Health
Dr. Koduri is a program director in the Division of Training, Workforce Development, and Diversity, where she manages the Maximizing Access to Research Careers (MARC) Undergraduate Student Training in Academic Research (U- STAR) program, Initiative for Maximizing Student Development (IMSD) program and predoctoral T32 pharmacological sciences training program. She also manages research grants in the areas of receptors, drug targets and signal transduction in the Division of Pharmacology, Physiology, and Biological Chemistry.
Koduri was formerly a scientific review officer at National Center for Advancing Translational Sciences and prior to that she worked as a senior scientist at BioReliance. She earned a BS in chemistry from Nagarjuna University and a PhD in biochemistry from the Central Food Technological Research Institute, both in India. Koduri conducted postdoctoral research at the Howard University College of Medicine and National Cancer Institute.
"It has been a long scientific journey and I would be happy to share my experiences."
Top of Page
Beverly D. Lyn-Cook, PhD
Senior Research Biologist
FDA-National Center for Toxicological Research
Dr. Lyn-Cook is a senior research scientist in the Division of Biochemical Toxicology. Currently, she serves as the coordinator of the Women's Health Research Program at the National Center for Toxicological Research (NCTR), a national laboratory of the Food and Drug Administration (FDA) located in Jefferson, Arkansas. Prior to her arrival at the FDA in 1988, Dr. Lyn-Cook was a research associate professor at the Lineberger Cancer Research Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (1984-1988).
Prior to her work at the cancer center, she was a postdoctoral fellow in the Department of Biochemistry (neurochemistry) at the University of North Carolina-Chapel Hill from 1981 to 1984. She received her bachelor of science degree from Fort Valley State College in 1977. Dr. Lyn-Cook received her master's degree in 1979 and doctoral degrees in biology from Atlanta University in Atlanta, Georgia in 1981. Her research interests include cancer research, with a focus on pancreatic and breast cancer, sex differences in drug response, lupus and regulatory science. Dr. Lyn-Cook has been a member of the American Association for Cancer Research for over 20 years, where she has served on numerous committees of the MICR Council. Currently, she serves as the first vice president of the Bluff Chapter of the Federally Employed Women (FEW) organization. She has served in the past as region VI (Texas, Arkansas, Oklahoma, New Mexico and Louisiana) president of Blacks in Government (BIG) and on its National Board of Directors. She was instrumental in establishing the Arkansas School for Math and Science in Hot Springs, AR where she was first appointed by Governor Clinton on its Advisory Board and later appointed by Governor Tucker to serve on its first Board of Trustees. She was appointed by Governor Beebe to the Arkansas Science and Technology Board for two terms, which she chaired in 2012 and was recently appointed by Governor Beebe to the Bioscience Institute Board. She currently serves as NCTR's liaison to the FDA, Office of Women Health. She is a member of the University of Arkansas at Pine Bluff (UAPB) STEM External Advisory Board and an adjunct faculty member in the Toxicology Department at the University of Arkansas Medical Sciences campus and the University of Arkansas at Little Rock. She has presented at numerous national and international meetings and published in numerous scientific journals.
Top of Page
Elena Martinez, PhD
Associate Director, Population Science, Disparities and Community Engagement
UCSD Moores Cancer Center
La Jolla, California
Dr. Martinez is a professor in the Department of Family Medicine and Public Health, having joined the UC San Diego faculty in 2012. She holds the Sam M. Walton Endowed Chair for Cancer Research and Co-leads the Community Outreach & Engagement core at the Moores Cancer Center. Dr. Martinez holds a PhD in Epidemiology and a Master's in Public Health. Dr. Martinez's research interests in colorectal cancer prevention began during the conduct of her doctoral dissertation and extended into her post-doctoral studies at the Harvard School of Public Health. Prior to joining the UC San Diego faculty, she was Professor of Epidemiology in the Mel and Enid Zuckerman College of Public Health and was the Richard H. Hollen Professor of Cancer Prevention at the Arizona Cancer Center. She had a very active research portfolio at the University of Arizona, including RO1 funding and program leadership in a Program Project (PO1) and a Specialized Program of Research Excellence (SPORE) program. She has published extensively in areas of epidemiology, molecular epidemiology, and cancer prevention. Her research currently focuses on breast cancer in Hispanic women, with a prominent leadership role in the Ella Binational Breast Cancer Study.
She is currently co-PI of an NCI-funded UO1 grant assessing epidemiologic and epigenetic features of breast tumors occurring in the post-partum period in Hispanic women. In addition, she is a key member of the original investigative team that implemented a large Gates Foundation-funded consortium in six countries in Latin America focusing on Helicobacter pylori eradication and gastric cancer prevention. Nationally, she has established herself as a strong leader in the area of cancer health disparities; evidence of this is her appointment as recent chair of the American Association for Cancer Research Minorities in Cancer Research Council. In addition, she is senior editor of the Cancer Disparities section for the Cancer Epidemiology Biomarkers and Prevention journal. Dr. Martinez was a recipient of the 2013 Women Who Mean Business Award from the San Diego Business Journal. Dr. Martinez has served on the NCI's Board of Scientific Counselors and currently she is a member of the NCI's Board of Scientific Advisors. Dr. Martinez is a member of prestigious Blue Ribbon Panel of experts that informed the scientific direction and goals of Vice President Joe Biden's National Cancer Moonshot Initiative.
Sofia D. Merajver, MD, PhD
Professor of Internal Medicine & Epidemiology; Scientific Director, Breast Oncology; Director, Breast and Ovarian Cancer Risk Evaluation Program
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Prior to her work at the cancer center, she was a postdoctoral fellow in the Department of Biochemistry (Neurochemistry) at the University of North Carolina-Chapel Hill from 1981 to 1984. She received her bachelor of science degree from Fort Valley State College in 1977. Dr. Lyn-Cook received her master's degree in 1979 and doctoral degrees in biology from Atlanta University in Atlanta, Georgia in 1981. Her research interests include cancer research, with a focus on pancreatic and breast cancer, sex differences in drug response, lupus and regulatory science. Dr. Lyn-Cook has been a member of the American Association for Cancer Research for over 20 years, where she has served on numerous committees of the MICR Council. Currently, she serves as the first vice president of the Bluff Chapter of the Federally Employed Women (FEW) organization. She has served in the past as region VI (Texas, Arkansas, Oklahoma, New Mexico and Louisiana) president of Blacks in Government (BIG) and on its National Board of Directors. She was instrumental in establishing the Arkansas School for Math and Science in Hot Springs, AR where she was first appointed by Governor Clinton on its Advisory Board and later appointed by Governor Tucker to serve on its first Board of Trustees. She was appointed by Governor Beebe to the Arkansas Science and Technology Board for two terms, which she chaired in 2012 and was recently appointed by Governor Beebe to the Bioscience Institute Board. She currently serves as NCTR's liaison to the FDA, Office of Women Health. She is a member of the University of Arkansas at Pine Bluff (UAPB) STEM External Advisory Board and an adjunct faculty member in the Toxicology Department at the University of Arkansas Medical Sciences campus and the University of Arkansas at Little Rock. She has presented at numerous national and international meetings and published in numerous scientific journals.
"Read both clinical and lab bench or computational or health systems papers. There can be no balance, if there is anxiety about keeping up with the knowledge base to excel in both. Read the New York Times. It is a great source of information about health topics of importance to practicing physicians in all specialties. Become active in Twitter and start to follow colleagues and thought leaders. Nurture professional friendships with women, minorities, and health professionals of all kinds, not just MDs or PhDs, to get a comprehensive view of what patents experience."
Top of Page
Kim L. O'Neill, PhD
Professor of Microbiology and Molecular Biology
Brigham Young University
Dr. O'Neill obtained his DPhil from the Biomedical Sciences Research Center at the University of Ulster in Northern Ireland; he was recruited to the department of Microbiology and Molecular Biology Brigham Young University in 1992. Dr. O'Neill has published over 140 peer reviewed papers, given over 1,000 presentations at National and International meetings and currently is listed as the inventor on eight patents. His research focuses on three areas: cancer prevention, biomarkers for early detection of disease, and immunotherapy. He has co-authored a book on the benefits of eating fruits and vegetables, his research has discovered a biomarker that is useful in early cancer diagnosis and prognosis, and currently his lab studies the relationship between the immune system and tumor development. Cancer often develops because of a failure of the immune system to recognize tumor cells; tumor cells also have the ability to suppress the immune system. By studying the interactions between cancer cells and the immune system his lab is developing methods to re-educate the immune system to help it recognize and attack tumors. Currently his research team produce CAR T cells, T cells that are genetically engineered with the ability to recognize and attack the tumors.
"Mentors should be willing to share skills, knowledge, and expertise. Mentors should be a positive role model, but be critical when it is constructive. Mentors should be approachable and take a personal interest in the mentoring relationship. Mentors should be an expert in the field, be knowledgeable, compassionate, understanding, and be able to point you in the right directions. Mentors should demonstrate their love for the subject, and exhibit ongoing learning in the field. Mentors should be actively involved in publishing, grant writing, and attending and presenting at conferences national and international. Mentors are human they do not know everything, but they should always act as a good role model."
Top of Page
Electra D. Paskett, PhD, MSPH
Professor and Chair, Division of Cancer Prevention and Control, Department of Internal Medicine
College of Medicine, Ohio State University
Dr. Paskett became the Marion N. Rowley professor of cancer research at The Ohio State University in 2002. She is the director of the Division of Cancer Prevention and Control in the College of Medicine, a professor in the Division of Epidemiology in the College of Public Health and the associate director for Population Sciences and Community Outreach and program leader of the Cancer Control Program in the Comprehensive Cancer Center of the Ohio State University (OSU). She is also director of the Center for Cancer Health Equity at the James Cancer Hospital. She received her doctorate in epidemiology from the University of Washington. Dr. Paskett's 344 peer-reviewed publications showcase her work in intervention research directed at cancer prevention, early detection and survivorship issues. Her studies use multi-level interventions in transdisciplinary teams with community-based participatory research to identify and intervene on factors causing disparities among underserved populations such as social and ethnic minority groups and rural/underserved populations. Dr. Paskett was elected as a fellow to the American Association for the Advancement of Science in 2004. She is a past-president of the American Society of Preventive Oncology, former deputy editor of the journal Cancer, Epidemiology, Biomarkers & Prevention, and current section editor of the journal, Cancer. She also has numerous awards such as the American Society of Preventive Oncology Distinguished Achievement Award, The Alliance for Clinical Trials in Oncology Jimmie Holland Award, the American Association for Cancer Research (AACR) Distinguished Lecture Award on the Science of Cancer Health Disparities and the AACR Team Science Award for her long standing role in the WHI. In 2016, she became a member of the National Cancer Institute's National Cancer Advisory Board.
"Success doesn't come easily. If you work hard, however, choose good mentors, and take opportunities as they arrive, you can be successful."
Top of Page
Timothy R. Rebbeck, PhD
Vincent L Gregory Jr. Professor of Cancer Prevention
Harvard School of Public Health and Dana-Farber Cancer Institute
Dr. Rebbeck is the professor of cancer epidemiology, at the Harvard TH Chan School of Public Health and Dana Farber Cancer Institute. His research focuses on the genetic and molecular epidemiology of cancer. Dr. Rebbeck has directed multiple molecular epidemiologic studies and international consortia to identify and characterize genes that are candidates for involvement in cancer etiology, and to describe the relationship of allelic variation with biochemical or physiological traits, cancer occurrences, and cancer outcomes. His research also focuses on the roles of these factors on prostate cancer disparities and prostate cancer in Africa. Dr. Rebbeck’s research uses a multidisciplinary approach that combines methods from epidemiology, statistics, molecular biology, and classical genetics.
It's not enough to just work hard. It's not enough to do a great job. To be successful, you need to learn how to really communicate and connect with others. Connecting is the ability to identify with people and relate to them in a way that increases your influence with them. - John Maxwell
Top of Page
Victoria M. Richon, PhD
President and CEO
Ribon Therapeutics, Inc.
Lexington, MassachusettsCareers in Cancer: Industry – Table #14
Dr. Richon is a scientifically trained executive with leadership experience in small biotechnology companies, global pharmaceutical companies and academia. Currently, Dr. Richon is the president and CEO of Ribon Therapeutics, a biotechnology company focused on the discovery and development of new cancer medicines. Before joining Ribon, Dr. Richon was the vice president and global head of oncology research and translational medicine at Sanofi where she was responsible for the oncology drug discovery and translational medicine portfolio. Prior to Sanofi, Dr. Richon was vice president of biological sciences at Epizyme Inc., a biotechnology company pioneering the discovery and development of first-in-class therapeutics focused upon epigenetics, including the EZH2 inhibitor tazemetostat. Earlier in her career, she was founder and executive director of Aton Pharmaceuticals which was acquired by Merck & Co. Aton was formed to develop HDAC inhibitors, including vorinostat, the first HDAC inhibitor approved by the FDA.
Dr. Richon is the author of over 100 papers and carried out postdoctoral studies at Memorial Sloan-Kettering Cancer Center. She received her PhD in biochemistry at the University of Nebraska Medical Center and a BA in chemistry at the University of Vermont.“As you progress in your career it is important to follow your passions, work hard in your current position and embrace new opportunities.”
Top of Page
Judith S. Sebolt-Leopold, PhD
Co-director, Experimental Therapeutics Program
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Dr. Sebolt-Leopold is co-director of the Experimental Therapeutics Program at the University of Michigan Comprehensive Cancer Center. She is a principal investigator in the Translational Oncology Program at UMCCC where her laboratory is focused on the design of combination therapies targeting KRAS mutant cancers.
Before joining the University of Michigan in 2009, Dr. Sebolt-Leopold served as executive director of the Mechanistic and Target Biology Department at Pfizer Global R&D, Ann Arbor Laboratories. In this role, she led a group of over 100 scientists dedicated to early stage drug discovery activities, encompassing molecular pharmacology, assay development, and biomarker validation. She has 23 years of pharmaceutical industry experience and has led multiple research teams, resulting in the advancement of four oncology clinical candidates, including the first clinically tested MEK inhibitor. She has an international reputation in kinase inhibitor development and has pioneered and championed the viability of MEK inhibitors from early discovery through clinical development.
Dr. Sebolt-Leopold received her undergraduate degree from Wellesley College and a doctorate in biological sciences from Purdue University. She carried out postdoctoral studies in tumor biochemistry at the Indiana University School of Medicine under the mentorship of Dr. George Weber. She has a publication record that includes over 80 peer-reviewed articles, invited reviews, and issued patents.Top of Page
Victoria Seewaldt, MD
Professor, Population Science
City of Hope
Los Angeles, California
Dr. Seewaldt is a translational researcher who investigates the biological origins of aggressive breast cancer in Latinas and African Americans. Dr. Seewaldt was told at the beginning of my career that she would fail - but she did not fail. Am here she is to help new investigators get funded.
"If you want to go fast, go alone. If you want to go far, go together"Top of Page
Christopher Sistrunk, PhD
Assistant Professor, Department of Population Sciences
City of Hope
Louis M. Staudt, MD, PhD
Co-chief of the Lymphoid Malignancies Branch, NIH Distinguished Investigator, and Director of the Center for Cancer Genomics
NCI-Center for Cancer Research
Dr. Staudt received his BA from Harvard College in 1976, graduating cum laude in biochemistry. He received his MD and PhD degrees in 1982 from the University of Pennsylvania. His PhD thesis revealed somatic hypermutation as a mechanism of rapid antibody diversification during normal immune responses. Following internal medicine training, he joined David Baltimore's laboratory at the Whitehead Institute where he cloned and characterized the first tissue specific transcription factor, Oct-2. In 1988, he established his laboratory at the National Cancer Institute (NCI), which now focuses on the molecular basis for human lymphoid malignancies and the development of targeted therapies for these cancers. Dr. Staudt is currently co-chief of the Lymphoid Malignancies Branch in the NCI. In addition, he serves as director of the NCI Center for Cancer Genomics, which oversees several large-scale managed programs studying the genomic aberrations in cancer. In 2011, Dr. Staudt was given the honorary title of NIH distinguished investigator. He has received numerous awards for his research, including the 2009 Dameshek Prize from the American Society of Hematology for outstanding contribution in hematology and election to the National Academy of Sciences in 2013.
Mariana C. Stern, PhD
Professor, Preventive Medicine and Urology; Director, Graduate Programs in Molecular Epidemiology
Keck School of Medicine of USC; Norris Comprehensive Cancer Center
Los Angeles, California
Dr. Stern is a professor in the Departments of Preventive Medicine and Urology at the Keck School of Medicine of USC, a member of the USC Norris Comprehensive Cancer Center, and director of graduate programs in molecular epidemiology. Dr. Stern obtained her undergraduate degree in biology from the University of Buenos Aires School of Science, her PhD in cancer biology from the University of Texas, MD Anderson Cancer Center, and obtained postdoctoral training in epidemiology at the National Institute of Environmental Health Sciences (NIEHS). Dr. Stern's research has focused on identifying genetic and environmental risk factors for various cancers, including colorectal and prostate cancer, with an interest on the role of dietary factors as potential sources of carcinogenic exposures, with many of these studies including Latinos and African-Americans. Her contributions include being a co-author of two monographs from the International Agency of Research in Cancer (IARC/WHO) on the carcinogenic risks of consumption of red meat and processed meats, and coffee and hot beverages. Dr. Stern also studies cancer patterns and tumor characteristics among Latino populations, taking into account sources of heterogeneity within this group, as well as clinical epidemiology of prostate cancer among Latinos and African-Americans. Dr. Stern is a member of the Minorities in Cancer Research group of the American Association of Cancer Research, and has served in the Scientific Program committee of the AACR Science of Cancer Health Disparities conference, the Latino Cancer Summit, and the inaugural conference of Advancing the Science of Cancer in Latinos. Dr. Stern is committed to advancing the knowledge of cancer in Latinos, mentoring the next generation of cancer disparity researchers, and attracting underrepresented minority students to cancer health disparities research.
Top of Page
Elizabeth Travis, PhD
Associate Vice President for Women and Minority Faculty Inclusion and the Mattie Allen Fair Professor in Cancer Research, Women and Minority Faculty Inclusion
MD Anderson Cancer Center
Dr. Elizabeth Travis is associate vice president for Women and Minority Faculty Inclusion and the Mattie Allen Fair professor in cancer research at the University of Texas, MD Anderson Cancer Center. She is responsible for oversight and strategic planning for the recruitment, retention and advancement of women faculty into senior ranks and leadership positions. Dr. Travis received her PhD degree in experimental pathology from the University of South Carolina. A distinguished biomedical researcher in the area of radiation oncology, she has been on the faculty at The University of Texas MD Anderson Cancer Center since 1982 and was promoted to professor in 1988. Dr Travis is a pioneer in the study of pulmonary complications of cancer therapy and is widely recognized as an expert in this field. She has written or contributed to chapters on lung complications for many textbooks and has authored or co-authored more than 125 original publications. She is past-president of the Radiation Research Society, and the first radiobiologist to be elected to the Board of Directors for the American Society for Therapeutic Radiology and Oncology. In recognition of her seminal contributions to our understanding of radiation complications in normal tissues, she was elected as a fellow of the American Society of Radiation Oncology (FASTRO) in 2007. In November 2007, Dr. Travis was appointed to serve as MD Anderson's first associate vice president for women faculty programs, which became Women and Faculty Minority Inclusion in 2016. In 2009 she was awarded the Women in Medicine Leadership Development Award from the Association of American Medical Colleges.
"If Leadership is your goal, mentors are good but sponsors are better."
Assistant Professor, Department of Surgery
The University of Florida- Gainesville
Dr. Treviño joined the University of Florida’s division of general surgery’s pancreatobiliary service in August 2011. Dr. Treviño earned his medical degree (MD) and completed his surgical residency at University of Illinois at Chicago. He was a research fellow in cancer biology at University of Texas M.D. Anderson Cancer Center in Houston and a clinical/research fellow in surgical oncology/tumor biology at H. Lee Moffitt Cancer Center & Research Institute in Tampa. Although his clinical focus is on liver, bile duct and pancreas surgery, his basic science research interests include pancreatic cancer biology with an emphasis on the tumor microenvironment’s contribution to cancer signaling and chemoresistance.
Professor and co-Program Leader, Immunology, Microenvironment and Metastasis
Born in Sri Lanka and raised in Southern Africa, Weeraratna first came to the United States in 1988 to study biology at St. Mary’s College of Maryland. She earned a PhD in molecular and cellular oncology at the Department of Pharmacology of George Washington University Medical Center. From 1998 to 2000, she was a postdoctoral fellow at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Oncology Center, before joining the National Human Genome Research Institute as a staff scientist. In 2003, she moved to the National Institute on Aging, where she started her own research program. Weeraratna joined The Wistar Institute in 2011. Dr. Weeraratna is an expert in melanoma metastasis, Wnt signaling, and aging, and her research focuses heavily on the effects of the tumor microenvironment on metastasis and therapy resistance. She has published over 100 scientific articles, including in top journals including Nature, Cancer Cell and Cancer Discovery. Her efforts provide insight into the mechanistic underpinnings of melanoma metastasis, therapy resistance and the influences of the tumor microenvironment.
Through speaking engagements and social media, Dr. Weeraratna diligently promotes sun awareness and is also a fierce champion of and a mentor for women in science.“Being a good leader means leading by example, always listen to what people have to say, and surround yourself with people who contribute to the mission, and not only to themselves. Rely on mentors beyond the walls of your own institution- they will always be more objective.”
Danny R. Welch, PhD
Professor of Cancer Biology
University of Kansas Cancer Center
Kansas City, Kansas
Hunt for the Right Postdoc Position: Career Transitioning from Graduate School to Fellow – Table #22
Dr. Welch is a cancer biologist whose laboratory has is best recognized for contributions to understanding the genetic basis of metastasis, having discovered eight metastasis suppressor genes. His laboratory is studying how the metastasis suppressors function and is designing therapies to take advantage of their mechanisms of action. He is author of more than 200 peer-reviewed publications and more than 20 book chapters. He has trained 12 graduate students and 23 postdoctoral fellows, all of whom have obtained research positions in cancer research in academia, industry, and government.
After receiving a BS in biology from the University of California-Irvine and a PhD in biomedical sciences at the University of Texas-Houston, Welch worked in the pharmaceutical industry studying cancer biology and virology before joining Pennsylvania State University College of Medicine. While in Hershey, Dr. Welch served as a member of the ACS Pennsylvania Division board of directors and founding director of the National Foundation for Cancer Research Center for Metastasis Research. In 2002, his laboratory moved to the University of Alabama - Birmingham as the Leonard H. Robinson professor of pathology and as a senior member in the UAB Comprehensive Cancer Center, Center for Metabolic Bone Disease, Gene Therapy Center, Skin Diseases Research Center, Center for Biophysical Sciences and Engineering and the Biomedical Engineering and Regenerative Medicine Center.
In 2011, he founded the Department of Cancer Biology at the University of Kansas Cancer Center, was named Hall Family Foundation endowed chair in molecular medicine, Kansas Bioscience Authority eminent scholar and associate director for basic sciences and education at the NCI-designated University of Kansas Cancer Center. He also developed the graduate programs in cancer biology at the University of Kansas and is faculty advisor for the KUMC Postdoctoral Association. He is a Komen scholar and past-president of the Metastasis Research Society and the Cancer Biology Training Consortium. He has served on numerous grant review panels for the NIH, DOD, ACS, Komen, European Union as well as other international agencies in addition to his service in numerous roles for AACR and as deputy editor of Cancer Research.
“The key to success is a combination of working hard, working smart, and persistence.”
Director, Center for Cancer Training
National Cancer Institute
Dr. Jonathan S. Wiest bachelor’s degree is in analytical chemistry from the University of Wisconsin-Milwaukee in 1980. Dr. Wiest received a PhD in biochemistry in 1988 and did a postdoc at the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina. He rose to the rank of senior staff fellow and then assisted in establishing a Cancer Research Institute in western Colorado. In 1996, he became an assistant professor at the University of Cincinnati, Department of Environmental Health, School of Medicine. Dr. Wiest joined the Center for Cancer Research at the National Cancer Institute as the associate director for training and education in 2001. In 2008, the NCI director appointed Dr. Wiest to lead the formation of the Center for Cancer Training (CCT) as the director. The CCT coordinates the major training activities at NCI in both the intramural and extramural communities. In 2003, Dr. Wiest received the NIH Director’s award for Mentoring as well as the NCI Outstanding Mentor award. In 2007 he received an NIH Award of Merit for mentoring. In 2015, the Center for Cancer Training received the Distinguished Service Award from the National Postdoctoral Association at the annual meeting. The major focus of his research involves genetic alterations in lung tumorigenesis. He is involved in studies to identify tumor suppressor genes and altered signaling pathways in lung cancer. Top of Page
University of Illinois Cancer Center
Dr. Winn is the associate vice chancellor for community based practice and director of the University of Illinois Cancer Center at the University of Illinois Hospital and Health Sciences System (UI Health). Dr. Winn is a professor of medicine at the University of Illinois at Chicago (UIC), Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine.
As associate vice chancellor, Dr. Winn is responsible for the management of the UI Health Mile Square Health Center, a 13-site Federally Qualified Health Center Network. Mile Square Health Center is dedicated to providing health care for the medically underserved populations in Chicago's South and West Side neighborhoods. The goal of Community Based Practice at UI Health is to integrate and coordinate healthcare for the communities we serve; build a 21st century model of community-based health care providers linked to the mission of our academic health center; and develop meaningful research programs that can be integrated into the community.
The UI Cancer Center is a robust organization comprised of 258 cancer researchers, representing four University of Illinois campuses: Champaign-Urbana, Chicago, Peoria, and Rockford; 11 colleges, including Engineering, Veterinary Medicine, Agriculture, Consumer, and Environmental Sciences and six health sciences colleges of Applied Health Sciences, Dentistry, Nursing, Medicine, Pharmacy, and the School of Public Health. The mission of the Cancer Center is to provide all Illinoisans access to cutting-edge treatment, innovative clinical trials, preventive and community health through creative educational and outreach programs designed to prevent and cure cancer.
Dr. Winn, an NCI-funded physician-scientist, has extensive experience in lung cancer research, both as a clinician and a researcher. Clinically, he is a specialist in pulmonary and critical care with a primary interest in lung cancer, and his laboratory focuses on the tumor predictive role of the Wnt pathway. He has laid the groundwork for developing effective and consistent in vitro and in vivo assays to investigate the tumor suppressive role of Wnt 7a in non-small cell lung cancer.
Dr. Winn received his medical degree from the University of Michigan Medical School in Ann Arbor, Michigan, and completed his medical residency in internal medicine at Rush Presbyterian St. Luke’s Medical Center in Chicago, where he was also a chief resident. He completed his fellowship in pulmonary/critical care medicine at the University of Colorado School of Medicine (CU)/National Jewish Health.
Prior to UI Health, Dr. Winn was an associate professor in the Department of Medicine, Division of Pulmonary/Critical Care Medicine at the University of Colorado Health Sciences Center. He was also an associate dean of admissions for the School of Medicine, vice chair of medicine, for the Department of Medicine, and the senior medical director for the University of Colorado Multidisciplinary Pulmonary Clinic. As a specialist in pulmonary and critical care, he practiced at both the University Hospital and the Veteran Affairs Medical Center in Denver, both in ambulatory medicine and the intensive care unit. Dr. Winn has led and served on a number of diverse committees to develop the next generation of physician-scientists. He has received numerous awards for excellence in teaching, scholarship, leadership, and diversity service.
Top of Page
Professor, Department of Biology and Center for Cancer Research
Dr. Clayton Yates is a professor in Department of Biology and hold joint appoints in the Center for Cancer Research, and Materials Science and Engineering at Tuskegee University. Before joining Tuskegee University, Dr. Yates completed his graduate training in Department of Pathology at University Pittsburgh School of Medicine. Dr. Yates further completed his postdoctoral training in Department of Urology, at Emory University School of Medicine. Dr. Yates has an interest prostate and breast cancer research, particularly in African-Americans. Dr. Yates as established several cell based models to study molecular events the lead prostate cancer development and metastasis. Dr. Yates has also received numerous research honors and awards, authored 45 peer-reviewed publications, set on numerous Dod and NIH study section panels, and received numerous DOD and R level NIH grants in the area of prostate and breast cancer health disparities. Dr. Yates is currently RCMI PI at Tuskegee, site PI of CTSA (jointly with UAB), and co-PI of U54 Cancer Health Disparities with Morehouse School of Medicinal and University of Alabama at Birmingham.
Top of Page
We would encourage you to take advantage of this exclusive opportunity for "face time" with leaders in the cancer research field by attending this sessions during the Annual Meeting! If you have any further questions or concerns, please contact our staff at email@example.com
Top of Page